Review article · 2022 · Open access
Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA
Clinical Therapeutics, 44(2), 306–322 · Published 21 January 2022 · DOI 10.1016/j.clinthera.2021.12.010
In brief
“Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA” is a 2022 review article by Sarah Mofid and 2 co-authors, published in Clinical Therapeutics. OpenAlex counts 61 citations as of 22 November 2026, which puts it in the top 6% of works published in 2022 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Therapeutics.
- Citations
- 61
- Most cited in
- 2025 (18)
- Field-weighted impact
- 1.41
- References
- 6
- Authors
- 3
Abstract
PURPOSE: This article provides an analysis of the various regulatory decisions available in the public domain that suggest the use of real-world data (RWD) for postmarketing surveillance activities of products that have a marketing authorization approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The study focuses on the cases in which RWD was used for postapproval commitments or requirements (and to a lesser extent label extensions, as this has been previously published) of medicinal products comprising small molecules and biologics to support efficacy claims or confirm an acceptable safety profile. METHODS: Clarivate Analytics was commissioned to collect data from cases in which RWD was used in the postapproval settings submitted to the EMA (data were found covering the last 14 years) and the FDA (data were found spanning 23 previous years). The query resulted in 165 cases in which regulatory approval was associated with RWD. The data were then categorized and expanded with supporting information gathered from public databases and company websites. FINDINGS: The use of RWD to support regulatory decision-making in the postmarketing surveillance setting has increased in recent years. Most postmarketing surveillance activities are legally enforced requests on the marketing authorization holder to further document the product's safety profile. Data drawn from registries tend to be the most common source in this regard. IMPLICATIONS: RWD have increasingly been used in recent years, both for new product approvals and line extensions and, as shown in this study, in the postapproval setting. There is now a growing appreciation of the potential of RWD as a source in its own right to support regulatory decision-making on the benefits and risks associated with clinical interventions.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mofid, S., Bolislis, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. Clinical Therapeutics, 44(2), 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010
MLA 9
Mofid, Sarah, et al. “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.” Clinical Therapeutics, vol. 44, no. 2, 2022, pp. 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010.
Chicago
Mofid, Sarah, Winona Rei Bolislis, and Thomas C. Kühler. 2022. “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.” Clinical Therapeutics 44 (2): 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010.
Harvard
Mofid, S., Bolislis, W. R. and Kühler, T. C. (2022) ‘Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA’, Clinical Therapeutics, 44(2), pp. 306–322. doi:10.1016/j.clinthera.2021.12.010.
IEEE
S. Mofid, W. R. Bolislis, and T. C. Kühler, “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA,” Clinical Therapeutics, vol. 44, no. 2, pp. 306–322, 2022, doi: 10.1016/j.clinthera.2021.12.010.
BibTeX
@article{mofid2022real,
title = {{Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA}},
author = {Mofid, Sarah and Bolislis, Winona Rei and Kühler, Thomas C.},
journal = {Clinical Therapeutics},
year = {2022},
volume = {44},
number = {2},
pages = {306--322},
doi = {10.1016/j.clinthera.2021.12.010},
url = {https://doi.org/10.1016/j.clinthera.2021.12.010}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 3 | |
| 2023 | 11 | |
| 2024 | 13 | |
| 2025 | 18 | |
| 2026 | 16 |
Its field-weighted citation impact is 1.41: it has been cited 1.41 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- real-world data
- post-marketing surveillance
- regulatory decision-making
- European Medicines Agency
- US Food and Drug Administration
- drug approval
- registry
- drug safety
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Mofid, S., Bolislis, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. Clinical Therapeutics, 44(2), 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010
How many times has this paper been cited?
61 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Therapeutics: sign in and open the full text from this page.
Who wrote this paper?
Sarah Mofid, Winona Rei Bolislis, Thomas C. Kühler.
What is the DOI of this paper?
10.1016/j.clinthera.2021.12.010, permanently at https://doi.org/10.1016/j.clinthera.2021.12.010. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.